ECX.F · Epigenomics AG

-

Please sign in to comment on ECX.F

1 Comment

Admin

4 years ago

Epigenomics AG is currently in a long term downtrend where the price is trading 35.1% below its 200 day moving average.

From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.5.

Epigenomics AG's total revenue rose by 8.3% to $301K since the same quarter in the previous year.

Its net income has increased by 63.2% to $-3M since the same quarter in the previous year.

Finally, its free cash flow grew by 22.4% to $-2M since the same quarter in the previous year.

Based on the above factors, Epigenomics AG gets an overall score of 4/5.

CurrencyCode	EUR
Exchange	F
ISIN	DE000A3H2184
Sector	Healthcare
Industry	Diagnostics & Research

Beta	1.21
Target Price	5.32
Dividend Yield	0.0%
Market Cap	6M
PE Ratio	None

ABOUT

Epigenomics AG

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

ECX.F · Epigenomics AG

-

Epigenomics AG

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Epigenomics AG using a moving average strategy